Octagon Capital Advisors LP Has $14.91 Million Stock Holdings in Pharvaris (NASDAQ:PHVS)

Octagon Capital Advisors LP grew its position in Pharvaris (NASDAQ:PHVS - Free Report) by 25.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 778,000 shares of the company's stock after acquiring an additional 157,530 shares during the quarter. Pharvaris makes up approximately 2.5% of Octagon Capital Advisors LP's holdings, making the stock its 16th largest position. Octagon Capital Advisors LP owned 1.49% of Pharvaris worth $14,914,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Deutsche Bank AG increased its holdings in shares of Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock valued at $348,000 after acquiring an additional 2,087 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Pharvaris in the 4th quarter valued at approximately $64,000. Bank of America Corp DE increased its holdings in shares of Pharvaris by 205,286.7% in the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock valued at $591,000 after acquiring an additional 30,793 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock valued at $1,762,000 after acquiring an additional 76,188 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock valued at $8,510,000 after acquiring an additional 118,408 shares during the last quarter.

Pharvaris Price Performance

Shares of Pharvaris stock traded up $0.65 during trading on Friday, hitting $16.56. The stock had a trading volume of 40,381 shares, compared to its average volume of 74,303. The firm has a market cap of $865.92 million, a P/E ratio of -5.91 and a beta of -2.85. The business has a fifty day moving average of $15.38 and a two-hundred day moving average of $17.63. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, research analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday. JMP Securities boosted their price target on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.